Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02876224 · ClinicalTrials.gov registry record · Phase 1
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT02876224 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 51 participants.
The verdict
NCT02876224, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, single-arm, two-stage, Phase Ib study designed to assess the safety, tolerability, and pharmacokinetics of oral cobimetinib with intravenous (IV) atezolizumab and bevacizumab in participants with metastatic colorectal cancer (mCRC) who have received and progressed on at least one prior line of therapy that contained a fluoropyrimidine and oxaliplatin or irinotecan. There are two stages in this study: Stage 1 (safety run-in phase) and Stage 2 (dose expansion phase with two cohorts, an expansion cohort and a biopsy cohort).
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Cobimetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2016-09-30 |
| Est. Completion | 2019-06-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02876224
The ClinicalTrials.gov registry entry for NCT02876224 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT02876224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02876224 about?
NCT02876224 is a clinical study titled "Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors". This is an open-label, multicenter, single-arm, two-stage, Phase Ib study designed to assess the safety, tolerability, and pharmacokinetics of oral cobimetinib with intravenous (IV) atezolizumab and bevacizumab in participants with metastatic colorectal cancer (mCRC) who have received and progressed...
What is the current status of trial NCT02876224?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2016-09-30. Estimated completion is 2019-06-25.
What interventions are being tested in trial NCT02876224?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Cobimetinib (DRUG).
Who is sponsoring clinical trial NCT02876224?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.